Combination therapy with infliximab and methotrexate in recalcitrant mucocutaneous behç et disease

Cutis

Volumn 89, Issue 4, 2012, Pages 185-190

  Chan, Wai Ping ^a   Lee, Hyun Soo ^b  

^a Lee Skin Surgery Center   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; DRUG COMBINATION; FEMALE; HUMAN; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METHOTREXATE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863002050     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Criteria for diagnosis of Behçet's disease. Interntional Study Group for Behçet's Disease. Lancet. 1990; 335:1078-1080.
2. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61:ii51-ii53.
3. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54:213-220.
4. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 1st ed. London, England: Mosby; 2003.
5. Stanford MR. Behçet's syndrome. Br J Ophthalmol. 2003;87:381-382.
6. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol. 1997;14:21-32.
7. Verity DH, Wallace GR, Vaughan RW, et al. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003;87:1175-1183.
8. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med. 1999;341:1284-1291.
9. Oztas MO, Onder M, Gurer MA, et al. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behçet's disease. Clin Exp Dermatol. 2005;30:61-63.
10. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum. 1998;27:197-217.
11. Kontogiannis V, Powell RJ. Behçet's disease. Postgrad Med J. 2000;76:629-637.
12. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:148-155.
13. Siva A, Altintas A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347-357.
14. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44:2686-2692.
15. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-450.
16. Barnes CG. Treatment of Behçet's syndrome. Rheumatology (Oxford). 2006;45:245-247.
17. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford). 2001;40:473-474.
18. Pipitone N, Olivieri I, Cantini F, et al. New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol. 2006;18:3-9.
19. Triolo G, Vadalà M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis. 2002;61:560-561.
20. Remicade [package insert]. Malvern, PA: Centocor, Inc; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf. Revised April 2009. Accessed June 17, 2009.
21. Gulli S, Arrigo C, Bocchino L, et al. Remission of Behçet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003;4:19.
22. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003;49:599-600.
23. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002;41:1213-1214.
24. van den Bemt BJ, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study [published online ahead of print January 31, 2008]. Ann Rheum Dis. 2008;67:1697-1701.
25. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-715.
26. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-3443.
27. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.